BioMarin Q2 revenues $595M (+12% YoY), raises FY VOXZOGO guidance to $400-440M

BIOMARIN PHARMACEUTICAL INC

2023-Q2 EPS reported $0.56 revenue$1,191,690,000

Q2 total revenues $595.3M (+12% YoY); GAAP net income $56.0M ($0.29 diluted EPS); Non-GAAP income $105.2M ($0.54 diluted EPS).
Record H1 2023 revenues of $1.19B (+13% YoY); VOXZOGO Q2 sales surged 229% to $113.3M.
Full-year VOXZOGO revenue guidance raised to $400-440M (was $380-430M); GAAP net income guidance raised to $165-215M.
US approved ROCTAVIAN on June 29; commercial launch started; European reimbursement negotiations continue.
Pivotal program for VOXZOGO in hypochondroplasia to begin in Q4 2023; ongoing studies for age expansion and pipeline updates.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BIOMARIN PHARMACEUTICAL INC updated its the six months and second quarter ended June 30, 2023 guidance (reaffirmed).

Period: the six months and second quarter ended June 30, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On July 31, 2023, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its second quarter ended June 30, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

BIOMARIN PHARMACEUTICAL INC filing history →

Source: SEC EDGAR

accession 0001048477-23-000026

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.